Skip to NavigationSkip to content

UroGen and MD Anderson to collaborate on bladder cancer treatment

Published on 14/01/21 at 12:16pm

UroGen Pharma, a biopharmaceutical company dedicated to treating specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center have announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).

Under the agreement, MD Anderson and UroGen will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee, while UroGen will provide funding, developmental candidates, and other support.

The New York-headquartered company’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UGN-301, an immune checkpoint inhibitor, is delivered using UroGen’s proprietary RTGel platform to increase dwell time, which has been shown to significantly improve the effectiveness of intravesical therapy.

UGN-201 and UGN-301 are being developed to ablate tumours by non-surgical means in the treatment of HG-NMIBC. Non-clinical data suggest treatment with the combination of UGN-201 and an anti-CTLA4 antibody, delivered using UroGen's proprietary RTGel platform, may result in improved survival and decreased tumour size.

Dr Mark Schoenberg, Chief Medical Officer of UroGen Pharma, said: “We are pleased to enter into this collaboration with MD Anderson and its immunotherapy platform, which brings unique translational and clinical expertise in immuno-oncology.

“This agreement will help UroGen potentially bring next-generation immunotherapy to bladder cancer patients with a significant unmet need and limited clinical options other than bladder removal.”

James Allison, Chair of Immunology, Executive Director of the Immunotherapy Platform, and Co-Director of the Parker Institute for Cancer Immunotherapy at MD Anderson, also commented: “Immune checkpoint inhibitors have become important treatment options for many patients with bladder cancer, and we look forward to working with UroGen to advance new immunotherapy strategies with intravesical delivery.

“This novel delivery approach has the potential to limit the adverse events seen with systemic immunotherapy treatment while providing clinical benefit, which would represent a major advancement to patient care.”

Darcy Jimenez

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches